Dr. Myuri Ruthirakuhan
Dr. Myuri Ruthirakuhan
Post-doctoral Fellow, Sunnybrook Research Institute, University of Toronto
E-mail confirmado em
Citado por
Citado por
Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group
P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ...
European Psychiatry 54, 71-76, 2018
Pharmacological interventions for apathy in Alzheimer's disease
MT Ruthirakuhan, N Herrmann, EH Abraham, S Chan, KL Lanctôt
Cochrane Database of Systematic Reviews, 2018
Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review
M Ruthirakuhan, AC Luedke, A Tam, A Goel, A Kurji, A Garcia
Journal of aging research 2012, 2012
Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease
N Herrmann, M Ruthirakuhan, D Gallagher, NPLG Verhoeff, A Kiss, ...
The American journal of geriatric psychiatry 27 (11), 1161-1173, 2019
Is it time to revise the diagnostic criteria for apathy in brain disorders
P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ...
The 2018 international consensus group. Eur Psychiatry 2018; 54: 71 76, 2018
Diagnostic criteria for apathy in neurocognitive disorders
DS Miller, P Robert, L Ereshefsky, L Adler, D Bateman, J Cummings, ...
Alzheimer's & Dementia 17 (12), 1892-1904, 2021
The roles of apathy and depression in predicting Alzheimer disease: a longitudinal analysis in older adults with mild cognitive impairment
M Ruthirakuhan, N Herrmann, D Vieira, D Gallagher, KL Lanctôt
The American Journal of Geriatric Psychiatry 27 (8), 873-882, 2019
Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease
CS Liu, SA Chau, M Ruthirakuhan, KL Lanctôt, N Herrmann
CNS drugs 29 (8), 615-623, 2015
Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial
J Mintzer, KL Lanctôt, RW Scherer, PB Rosenberg, N Herrmann, ...
JAMA neurology 78 (11), 1324-1332, 2021
A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease
N Herrmann, J O'Regan, M Ruthirakuhan, A Kiss, G Eryavec, E Williams, ...
Journal of the American Medical Directors Association 17 (2), 142-147, 2016
Latrepirdine for Alzheimer's disease
S Chau, N Herrmann, MT Ruthirakuhan, JJ Chen, KL Lanctôt
Cochrane Database of Systematic Reviews, 2015
Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate, and severe Alzheimer's disease patients
S Mathur, A Glogowska, E McAvoy, C Righolt, J Rutherford, C Willing, ...
Journal of Alzheimer's Disease 39 (1), 35-48, 2014
Natural and synthetic cannabinoids for agitation and aggression in Alzheimer's disease: a meta-analysis
M Ruthirakuhan, KL Lanctôt, D Vieira, N Herrmann
The Journal of clinical psychiatry 80 (2), 2246, 2019
Biomarkers of agitation and aggression in Alzheimer's disease: a systematic review
M Ruthirakuhan, KL Lanctôt, M Di Scipio, M Ahmed, N Herrmann
Alzheimer's & Dementia 14 (10), 1344-1376, 2018
Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study
M Ruthirakuhan, Z Ismail, N Herrmann, D Gallagher, KL Lanctôt
Alzheimer's & Dementia 18 (11), 2199-2208, 2022
Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation
M Ruthirakuhan, N Herrmann, AC Andreazza, NPLG Verhoeff, ...
Journal of Geriatric Psychiatry and Neurology 33 (4), 175-184, 2020
Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
DR Bateman, S Gill, S Hu, ED Foster, MT Ruthirakuhan, AF Sellek, ...
Alzheimer's & Dementia: Translational Research & Clinical Interventions 6 (1 …, 2020
Pregnancy and delivery outcomes following benzodiazepine exposure: a systematic review and meta-analysis
S Grigoriadis, L Graves, M Peer, L Mamisashvili, M Ruthirakuhan, P Chan, ...
The Canadian Journal of Psychiatry 65 (12), 821-834, 2020
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
M Ruthirakuhan, N Herrmann, I Suridjan, EH Abraham, I Farber, ...
Expert opinion on pharmacotherapy 17 (18), 2417-2429, 2016
Pharmacological management of agitation and aggression in Alzheimer’s disease: a review of current and novel treatments
C S Liu, M Ruthirakuhan, S A Chau, N Herrmann, A F Carvalho, ...
Current Alzheimer Research 13 (10), 1134-1144, 2016
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20